Drug Cuts Lung Cancer Return Risk by 83% in UCLA Study

For patients who've beaten early-stage lung cancer, the fear of it coming back has always loomed large. Now, UCLA researchers have found a drug that could change that story completely.

A groundbreaking international study led by UCLA's Health Jonsson Comprehensive Cancer Center shows that the drug selpercatinib can slash the risk of cancer returning by 83% in patients with a rare genetic form of non-small cell lung cancer. The results were announced Sunday at the American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine.

The numbers tell a powerful story. After two years, 92% of patients with RET fusion-positive lung cancer who took selpercatinib after standard treatment were alive and cancer-free. Only 61% of patients who received a placebo had the same outcome.

Dr. Jonathan Goldman, a clinical professor at UCLA's David Geffen School of Medicine, led the research team. "Even when patients with early-stage RET-positive lung cancer undergo surgery and other standard treatments with curative intent, many still face the possibility that their cancer will return," he explained.

RET fusion-positive lung cancer affects fewer than 2% of non-small cell lung cancer patients. It's caused by abnormal rearrangements in the RET gene. While early-stage patients can be treated with surgery, radiation, and chemotherapy, many see their cancer return in more aggressive forms.

Selpercatinib works differently than traditional treatments. It's a targeted therapy designed to specifically block RET-driven cancer growth. The drug was already approved for advanced or metastatic RET-altered cancers, but this study marks the first time researchers tested whether it could help patients at earlier stages.

The LIBRETTO-432 trial involved patients with stage II-IIIA RET fusion-positive lung cancer who had completed standard treatment. This represented new territory, since no adjuvant targeted therapy currently exists for this patient group.

The most common significant side effects involved elevated liver enzymes, which doctors found manageable. Goldman noted this was an acceptable tradeoff for the dramatic reduction in cancer recurrence.

The Ripple Effect

This discovery goes beyond just one drug or one type of cancer. It highlights the growing importance of comprehensive biomarker testing, which helps doctors match patients with therapies tailored to their specific genetic profiles. Goldman emphasized this point, noting that early testing could help countless patients access treatments that dramatically reduce recurrence risk.

For patients living with the fear of cancer's return, this represents a new layer of protection after surgery. The research team plans to continue following study participants to understand the long-term benefits and whether the treatment improves overall survival rates.

Every cancer patient deserves the hope that their fight won't have to start over again, and this breakthrough brings that hope closer to reality.